News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Treatment with Teva Neuroscience, Inc. (TEVA)'s COPAXONE(R) Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis



5/4/2007 1:21:33 PM

KANSAS CITY, Mo.--(BUSINESS WIRE)--New data from a randomized, double-blind study showed that a combination of COPAXONE® (glatiramer acetate injection) along with the oral antibiotic minocycline reduced T1 Gadolinium (Gd)-enhancing lesions of the brain by 63 percent (p=0.08) in patients with active relapsing-remitting multiple sclerosis (RRMS), as measured by magnetic resonance imaging (MRI), compared to those receiving COPAXONE® alone. Additionally, the nine-month study demonstrated that treatment with COPAXONE® in combination with minocycline reduced the number of new T2 lesions in patients by 65 percent (p=0.06). These results trended toward but did not reach statistical significance.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES